June 27, 2024
Intracranial efficacy of datopotamab deruxtecan in patients with previously treated advanced/metastatic non-small cell lung cancer with actionable genomic alterations: results from tropion-lung 05 presented in the annual meeting of the American Society of Clinical Oncology in 2024 in Chicago
Related Posts
Dalmelitinib Plus Aumolertinib Shows Durable Activity in MET-Amplified, EGFR-Mutant NSCLC After Progression
Navigating Second-Line Treatment Decisions in EGFR+ NSCLC
Analysis Reveals Insights About Chemo Rechallenge After Progression on FLAURA2 Regimen in EGFR+ Advanced NSCLC
